4-July-2019: The global in-vitro
diagnostics infectious diseases market size is likely to
reach USD 31.45 billion by 2026, according to a new report by Grand View
Research, Inc., experiencing a CAGR of 6.7% during the forecast period.
Increasing geriatric population and rising consumer awareness regarding the
merits of IVD tests are expected to drive the IVD infectious diseases market.
Growing prevalence
of target diseases, health awareness, and high demand for self-care medical
devices are estimated to accentuate market growth over the forecast period.
Moreover, introduction of technologically advanced products with improved
sensitivity, speed, and user-friendliness are anticipated to increase the
adoption of in-vitro diagnostics for infectious diseases in the next few years.
Key IVD techniques
include immunochemistry assays, such as Enzyme-linked Immunosorbent Assay
(ELISA) and Immuno-agglutination. These are widely used in clinical
laboratories and diagnostic centers for detecting infectious microorganisms
such as bacteria and virus in patient samples.
North America
dominated the market, supported by presence of sophisticated healthcare
infrastructure, government initiatives pertaining to research & development
activities, and high awareness levels of patients and practitioners. The Asia
Pacific IVD infectious diseases market is projected to witness the fastest
growth over the forecast period.
In
depth research report on In IVD Infectious Diseases Market
Further key findings from the report suggest:
·
Introduction of technologies such as qPCR and ELISA has
enhanced usage rates of IVD products for infectious disease testing
·
High unmet consumer needs, supported by rising disposable
income and awareness levels in emerging markets, is a key growth stimulant
·
Immunochemistry assays, such as ELISA and chemiluminescence
immunoassays, are projected to be widely used over the forecast period
·
Molecular diagnostics is poised to witness strong growth,
driven by wide adoption and improved accuracy levels
·
Key players in the market include Becton Dickinson;
bioMerieux; Abbott Laboratories; Quidel Corporation; Alere Inc.; Orasure
Technologies, Inc.; Hologic Inc.; Cepheid; Qiagen N.V.; Roche Diagnostics;
Siemens Healthcare; and Bio-Rad Laboratories, Inc.
Grand View Research
has segmented the global IVD infectious diseases market based on product,
technology, application, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2026)
·
Instruments
·
Reagents
·
Software
Technology Outlook (Revenue, USD Million, 2014 - 2026)
·
Immunochemistry
·
Molecular Diagnostics
·
Microbiology
·
Others
Application Outlook (Revenue, USD Million, 2014 - 2026)
·
MRSA
·
Streptococcus
·
Clostridium difficile
·
VRE
·
CRE
·
Respiratory Virus
·
Candida
·
TB and Drug-resistant TB
·
Gastro-intestinal Panel Testing
·
Chlamydia
·
Gonorrhea
·
HPV
·
HIV
·
Hepatitis C
·
Hepatitis B
·
Others
End-use Outlook (Revenue, USD Million, 2014 - 2026)
·
Point of Care
·
Central Laboratories
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment